Our findings not only identified TCN‐PM as a potent STAT5 inhibitor, but also provided evidence for extending the use of this drug to AML patients carrying FLT3‐ITD mutation, which could serve as a biomarker for more precise application of TCN‐PM in clinical therapy. Here, FLT3 is linked to acute myeloid leukemia.